Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Advanced Ovarian Cancer (GOG-0218)
NCT00262847Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 6 years. Started Sep 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00262847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262847.